Loss-of-function of *MFGE8* and protection against coronary atherosclerosis

Sanni E. Ruotsalainen¹, Ida Surakka², Nina Mars¹, Juha Karjalainen³, Mitja Kurki³, Masahiro Kanai³⁻⁵, Kristi Krebs⁶, Pashupati P. Mishra⁷⁻⁹, Binisha H. Mishra⁷⁻⁹, Juha Sinisalo¹⁰, Priit Palta^{1,6}, Terho Lehtimäki⁷⁻⁹, Olli Raitakari¹¹⁻¹³, *Estonian Biobank research team*, Lili Milani⁶, *The Biobank Japan Project*¹⁴, Yukinori Okada^{5,15}, *FinnGen*, Aarno Palotie^{1,3}, Elisabeth Widen¹, Mark J. Daly^{1,3,4}, Samuli Ripatti^{1,3,16*}

- 1) Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
- 2) Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
- 3) The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
- 4) Analytic and Translational Genetics Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 5) Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan
- 6) Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
- 7) Department of Clinical Chemistry, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- 8) Finnish Cardiovascular Research Centre, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- 9) Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland
- 10) Heart and Lung Center, Helsinki University Hospital and Helsinki University, Helsinki, Finland
- 11) Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland
- 12) Centre for Population Health Research, University of Turku, Turku University Hospital, Turku, Finland
- 13) Department of Clinical Physiology and Nuclear Medicine, University of Turku, Turku, Finland
- 14) Institute of Medical Science, The University of Tokyo
- 15) Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
- 16) Department of Public Health, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland

*Corresponding author

Tel: +358 40 567 0826

E-mail: samuli.ripatti@helsinki.fi

1 Abstract

Cardiovascular diseases are the leading cause of premature death and disability worldwide, with both genetic and environmental determinants. While genome-wide association studies have identified multiple genetic loci associated with cardiovascular diseases, exact genes driving these associations remain mostly uncovered. Due to Finland's population history, many deleterious and high-impact variants are enriched in the Finnish population giving a possibility to find genetic associations for protein-truncating variants that likely tie the association to a gene and that would not be detected elsewhere.

9

In FinnGen, a large Finnish biobank study, we identified an inframe insertion rs534125149 in *MFGE8* to have protective effect against coronary atherosclerosis (OR = 0.75, p = 2.63×10^{-16}) and related endpoints. This variant is highly enriched in Finland (70-fold compared to Non-Finnish Europeans) with allele frequency of 3% in Finland. The protective association was replicated in meta-analysis of biobanks of Japan and Estonian (OR = 0.75, p = 5.41×10^{-7}).

15

Additionally, we identified a splice acceptor variant rs201988637 in *MFGE8*, independent of the rs534125149 and similarly protective in relation to coronary atherosclerosis (OR = 0.72, $p = 7.94 \times 10^{-06}$) and related endpoints, with no significant risk-increasing associations. The protein-truncating variant was also associated with lower pulse pressure, pointing towards a function of *MFGE8* in arterial stiffness and aging also in humans in addition to previous evidence in mice. In conclusion, our results show that inhibiting the production of lactadherin could lower the risk for coronary heart disease substantially.

23

24 Keywords: coronary atherosclerosis, myocardial infarction, loss-of-function, MFGE8

25 Introduction

Cardiovascular disease (CVD) is the leading cause of premature death and disability worldwide, with both genetic and environmental determinants^{1, 2}. The most common cardiovascular disease is coronary heart disease (CHD), including coronary atherosclerosis and myocardial infarction, among others. While genome-wide association studies (GWAS) have identified multiple genetic loci associated with cardiovascular diseases, exact genes driving these associations remain mostly uncovered³.

32

Due to Finland's population history, many deleterious and high-impact variants are enriched in the Finnish population giving a possibility to find genetic associations that would not be detected elsewhere⁴. Many studies have reported high-impact loss-of-function (LoF) variants associated with risk factors for CVD, such as blood lipid levels, thus impacting on the CVD risk remarkably. For example, high-impact LoF variants in genes *LPA*⁴, *PCSK9*⁵, *APOC3*⁶ and *ANGPTL4*⁷ have been shown to be associated with Lipoprotein(a), LDL-cholesterol (LDL-C) or triglyceride levels and lowering the CVD risk.

40

Besides blood lipids, other risk factors for CVD include hypertension, smoking and the metabolic syndrome cluster components. The mechanism that links these risk factors to atherogenesis, however, remains incompletely elucidated. Many, if not all, of these risk factors, however, also participate in the activation of inflammatory pathways, and inflammation in turn can alter the function of artery wall cells in a manner that drives atherosclerosis⁸.

46

47 Using data from a sizeable Finnish biobank study FinnGen ($n = 260\ 405$), we identified an inframe 48 insertion rs534125149 in *MFGE8* to protect against coronary atherosclerosis and related endpoints, 49 such as myocardial infarction (MI). This variant is highly enriched in Finland, 70- fold compared to

50	Non-Finnish Europeans (NFE) in the gnomAD genome reference database ⁹ with AF of 3% in Finland.
51	This association was also replicated in BioBank Japan (BBJ) and Estonian Biobank (EstBB). We also
52	identified a splice acceptor variant rs201988637 in the same gene, which is also protective against
53	coronary atherosclerosis-related endpoints, indicating that rs534125149 act as a loss-of-function
54	variant in MFGE8. Associations of functional variants in MFGE8 were specific to coronary
55	atherosclerosis-related endpoints, and they did not significantly ($p < 1.75 \times 10^{-5}$) increase risk for any
56	other disease, highlighting MFGE8 as a potential drug target candidate.

57

58 Material and methods

59 Study cohort and data

We studied total of 2 861 disease endpoints in Finnish biobank study FinnGen (n = 260 405) (**Table** 1). FinnGen (<u>https://www.finngen.fi/en</u>) is a large biobank study that aims to genotype 500 000 Finns and combine this data with longitudinal registry data, including national hospital discharge, death, and medication reimbursement registries, using unique national personal identification numbers. FinnGen includes prospective epidemiological and disease-based cohorts as well as hospital biobank samples.

66

67 Definition of disease endpoints

All the 2 861 disease-endpoint analysed in FinnGen have been defined based on registry linkage to national hospital discharge, death, and medication reimbursement registries. Diagnoses are based on International Classification of Diseases (ICD) codes and have been harmonized over ICD codes 8, 9 and 10. More detailed lists of the ICD codes used for the disease-endpoints myocardial infarction and coronary atherosclerosis, which are discussed more in this study, are in Supplementary Material. A

- 73 complete list of endpoints analysed, and their definitions is available at
 74 <u>https://www.finngen.fi/en/researchers/clinical-endpoints</u>.
- 75

76	Table 1: Basic characteristics of the study cohort.	
----	---	--

	All	Females	Males
N (%)	260 405	147 061 (56.47 %)	113 344 (43.53 %)
Age (mean (sd))	53.15 (17.55)	51.84 (17.71)	54.85 (17.19)
BMI (mean (sd)) ^a	27.29 (5.36)	27.21 (5.83)	27.38 (4.76)
Statin use (N (%))	86 466 (33.2 %)	40 422 (27.48 %)	46 044 (40.62 %)
Hypertension (N (%))	68 005 (26.11 %)	33 420 (22.72 %)	34 585 (30.51 %)
Smoking (N (%)) $^{\text{b}}$	1 733 (1.07 %)	901 (0.96 %)	832 (1.22 %)
Coronary atherosclerosis	28 598 (11.38 %)	9 252 (6.87 %)	19 346 (17.86 %)
Myocardial infarction	14 305 (6.04 %)	3 958 (2.87 %)	10 347 (10.42 %)

77

^a BMI is available only from 178 966 individuals

79 ^bSmoking information is available only from 98 654 individuals

80

81 Genotyping and imputation

82 FinnGen samples were genotyped with multiple Illumina and Affymetrix arrays (Thermo Fisher 83 Scientific, Santa Clara, CA, USA). Genotype calls were made with GenCall and zCall algorithms for 84 Illumina and AxiomGT1 algorithm for Affymetrix chip genotyping data batchwise. Genotyping data 85 produced with previous chip platforms were lifted over to build version 38 (GRCh38/hg38) following 86 the protocol described here: dx.doi.org/10.17504/protocols.io.nqtddwn. Samples with sex 87 discrepancies, high genotype missingness (>5%), excess heterozygosity (±4SD) and non-Finnish 88 ancestry were removed. Variants with high missingness (>2%), deviation from Hardy–Weinberg 89 equilibrium ($P < 1 \times 10^{-6}$) and low minor allele count (MAC < 3) were removed.

90

91 Pre-phasing 2.3.5 of genotyped data performed with Eagle was 92 (https://data.broadinstitute.org/alkesgroup/Eagle/) with the default parameters, except the number of 93 conditioning haplotypes was set to 20,000. Imputation of the genotypes was carried out by using the 94 population-specific Sequencing Initiative Suomi (SISu) v3 imputation reference panel with Beagle 95 4.1 (version 08Jun17.d8b, https://faculty.washington.edu/browning/beagle/b4_1.html) as described 96 in the following protocol: dx.doi.org/10.17504/protocols.io.nmndc5e. SISu v3 imputation reference 97 panel was developed using the high-coverage (25-30x) whole-genome sequencing data generated at 98 the Broad Institute of MIT and Harvard and at the McDonnell Genome Institute at Washington 99 University, USA; and jointly processed at the Broad Institute. Variant callset was produced with 100 Genomic Analysis Toolkit (GATK) HaplotypeCaller algorithm by following GATK best practices 101 for variant calling. Genotype-, sample- and variant-wise quality control was applied in an iterative manner by using the Hail framework v0.2. The resulting high-quality WGS data for 3 775 individuals 102 103 were phased with Eagle 2.3.5 as described above. As a post-imputation quality control, variants with 104 INFO score < 0.7 were excluded.

105

106 Association testing

A total of 260 405 samples from FinnGen Data Freeze 6 with 2 861 disease endpoints were analyzed using Scalable and Accurate Implementation of Generalized mixed model (SAIGE), which uses saddlepoint approximation (SPA) to calibrate unbalanced case-control ratios¹⁰. Models were adjusted for age, sex, genotyping batch and first ten principal components. All variants reaching genome-wide significance p-value threshold of 5×10^{-8} are considered as genome-wide significant (GWS), and all disease- endpoints reaching multiple testing corrected (for the number of endpoints tested = 2 861) p-value threshold of 0.05/2 861 = 1.75×10^{-5} were considered as phenome-wide significant (PWS).

115 Independent GWS loci for atherosclerosis were determined as adding ± 0.5 Mb around each variant 116 that reach the genome-wide significance threshold, overlapping regions were merged. The NHGRI-117 EBI GWAS Catalog¹¹ was used for assessing the novelty of the independent loci with any CVD-118 related endpoint or traditional risk factor for CVD, such as blood lipids, BMI and blood pressure. All 119 novel loci for CVD were fine-mapped using FINEMAP¹² to determine the credible sets in each signal. 120

121 In Corogene¹³ (n = 5300), a sub-cohort of FinnGen where participants have been collected as patients 122 with coronary artery disease CAD) and other related heart diseases, we tested the association of 123 rs534125149 with sub-types of coronary heart disease (acute coronary syndrome, stable coronary 124 heart disease (CHD) and other heart attacks). The acute coronary syndrome was further divided into 125 unstable Angina pectoris, non-ST segment elevation myocardial infarction (NSTEMI) and ST-126 segment elevation myocardial infarction (STEMI). Associations were tested by calculating risk ratios 127 (RR) for carriers vs. non-carriers of rs534125149 using non-CHD group always as controls and excluding the other tested groups from the analysis. P-values were calculated using χ^2 - test, and p-128 129 values < 0.05 were considered significant.

130

131 Survival analysis

132 133

Survival analysis for coronary atherosclerosis and myocardial was performed using GATE¹⁴, which accounts for both population structure and sample relatedness and controls type I error rates even for phenotypes with extremely heavy censoring. GATE transforms the likelihood of a multivariate Gaussian frailty model to a modified Poisson generalized linear mixed model (GLMM^{15, 16}), and to obtain well-calibrated p-values for heavily censored phenotypes, GATE uses the SPA to estimate the null distribution of the score statistic. For coronary atherosclerosis and myocardial infarction, survival time from birth to first diagnose was analyzed for both rs534125149 and rs201988637. Models were

adjusted for age, sex, genotyping batch and first ten principal components, similarly to originalGWAS analyses.

143

145

144 Replication and biomarker analyses

We tested the association of the two *MFGE8* variants (rs534125149 and rs201988637) with quantitative measurements of cardiometabolic relevance or known risk factors for CVD in two subcohorts of FinnGen, the population-based national FINRISK study¹⁷ (n = 26 717) and GeneRISK¹⁸ (n = 7 239). The associations were tested across 66 quantitative measurements of cardiometabolic relevance in FINRISK, and for 158 sub-lipid species in GeneRISK. In Young Finns Study (YFS)¹⁹ cohort (n = 1 934), we tested the association of the two variants with three measurements of arterial relevance (carotid artery distensibility, pulse wave velocity and pulse pressure).

153

154 In addition to Finnish cohorts described above, we tested the association of the two variants in 155 Estonian Biobank data (EstBB)^{20, 21}, BioBank Japan (BBJ)^{22, 23} and UK Biobank (UKBB)²⁴. In EstBB 156 (n = 51 388-137 722) we tested the associations of both variants with body mass index (BMI), systolic 157 and diastolic blood pressure (SBP and DBP) and pulse pressure (PP), in BBJ in we tested the 158 association of rs534125149 with 17 known quantitative risk factors for CVD and lastly, in the UKBB 159 we tested the association of rs201988637 with 79 measurements of cardiometabolic relevance. In all 160 of these biomarker analyses, a linear regression model adjusted for age and sex was used and for all 161 quantitative risk factors rank-based inverse normal transformation was applied prior to analysis. 162 Bonferroni corrected p-value threshold for the number of phenotypes tested was used to assess the 163 significance of resulting associations in each cohort.

164

For biomarkers that showed significant association in any of the cohorts, we performed a metaanalysis across all cohorts the measurement was available. Meta-analysis was performed using

167 inverse-variance weighted fixed-effects meta-analysis method^{25, 26}. Bonferroni corrected p-value for 168 number of traits tested (n = 2) was used to assess the significance of resulting associations in meta-169 analysis.

170

171 Identifying causal variants

We used FINEMAP¹² on the GWAS summary statistics to identify causal variants underlying the associations for MI (strict definition, i.e., only primary diagnoses accepted) and coronary atherosclerosis. FINEMAP analyses were restricted to a ± 1.5 Mb region around the rs534125149. We assessed variants in the top 95% credible sets, i.e., the sets of variants encompassing at least 95% of the probability of being causal (causal probability) within each causal signal in the genomic region. Credible sets were filtered if minimum linkage disequilibrium (LD, r²) between the variants in the redible set was < 0.1, i.e., not clearly representing one signal.

179

180 Results

181 GWAS results for Coronary Atherosclerosis

182 We identified a total of 2 302 variants associated (GWS, $p < 5 \times 10^{-8}$) with coronary atherosclerosis 183 (detailed description of the definition of the endpoint is in Supplementary Material). These variants 184 were located in 38 distinct genetic loci (a minimum of 0.5 Mb distance from each other; Figure 1). 185 Out of the 38 GWS loci, four (within or near genes MFGE8, TMEM200A, PRG3 and FHL1) were 186 novel for any CVD-related endpoints or risk factor for CVD compared to the GWAS Catalog¹¹ 187 [https://www.ebi.ac.uk/gwas/] (Supplementary Table 1). Lead variants in these novel loci and their 188 characteristics are listed in Table 2 and locus zoom plots for each of the loci are in Supplementary 189 Figure 1.

Among the three novel loci for coronary atherosclerosis, the locus near *MFGE8* had the strongest association (p-value = 2.63×10^{-16} for top variant rs534125149). The lead variant is an inframe insertion located in the sixth exon in the *MFGE8* gene (**Supplementary Figure 2**) and it is highly enriched in the Finnish population compared to NFSEEs (Non-Finnish, Estonian or Swedish Europeans). Interestingly, *MFGE8* is mainly expressed in coronary and tibial arteries according to data from GTEx v8 (**Supplementary Figure 3**).



198

199 *Figure 1:* GWAS results for coronary atherosclerosis in FinnGen. Total number of independent 200 genome-wide significant associations (GWS; $p < 5 \times 10^{-8}$) is 38, the lead variant in each marked with 201 diamonds. Four novel associations for CVD- related phenotypes are highlighted with ±750 Mb 202 around the lead variant in the region as red and the lead variant marked with red diamond.

In addition to *MFGE8*, we identified three additional novel loci to be associated with coronary atherosclerosis, *TMT200A*, *PRG3* and *FHL1* being the nearest genes of the lead variants. *TMT200A* and *PRG3* loci had one non-coding low-frequency variant reaching the genome-wide significance threshold, and *FHL1* had 11. All variants in the credible sets of all these associations were either

208 intergenic or intronic variants and had no reported significant GWAS associations with any trait in 209 the GWAS Catalog or significant eQTL associations in GTEx. The one variant (rs118042209) in the 210 credible set of TMEM200A locus was associated with multiple coronary atherosclerosis related 211 endpoints in FinnGen, including coronary atherosclerosis, ischemic heart disease and angina pectoris, 212 whereas the lead variant in the PRG3 locus was associated with several cardiomyopathy related 213 endpoints. All variants in the credible set of FHL1 were associated with multiple coronary 214 atherosclerosis and related endpoints in FinnGen, including angina pectoris and ischemic heart 215 disease. TMEM200A have been reported to be associated with ten traits (including height and trauma 216 exposure) and PRG3 with two traits (eosinophil count and eosinophil percentage of white cells) in 217 the GWAS Catalog. FHL1 gene had no reported associations in GWAS Catalog.

218

(able 2: Lead variants in novel loci associated with coronary atherosclerosis.								
Lead variant chrom:pos:ref_alt (rsid)	Most severe consequence	Nearest gene	FIN enrichment (NFE)	AF	OR (P-value)	Info	# cs (Post- pr)	# coding in cs(s)
chr15:88901702:C_CTGT (rs534125149)	Inframe insertion	MFGE8	70.59	0.029	0.75 (2.60×10 ⁻¹⁶)	0.99	2 (0.705)	1
chr6:130483492:A_G (rs118042209)	Intergenic variant	TMEM200A	0.87	0.010	0.7 (1.90×10-9)	0.91	1 (0.904)	0
chr11:57380633:A:G (rs764568652)	Intron variant	PRG3	_ a	0.0003	7.72 (4.10×10 ⁻⁸)	0.89	1 (0.583)	0
chrX:136194941:C_G (rs5974585)	Intron variant	FHL1	1.25	0.49	0.95 (2.55×10-08)	0.99	1 (0.692)	0

219

220

221 ^a Variant not present in NFE in gnomAD

- In the PRG3 locus the lead variant is 40.9 kb away from a variant (chr11:57340143:G:A 223
- 224 (rs11603691), the p-value for coronary atherosclerosis risk = 0.0269) which has previously been
- 225 reported to be associated with HDL- cholesterol (HDL-C). However, our association is independent

of the previously reported variant rs11603691 (p-value for rs764568652 in a conditional analysis =

227 4.36×10⁻⁰⁸)

- Replication and phenome-wide association results for rs534125149
- 230 We observed a highly protective association for the Finnish enriched inframe insertion rs534125149
- 231 in the MFGE8 gene and coronary atherosclerosis related endpoints, including coronary
- atherosclerosis (OR = 0.72 [0.63 0.83], p = 7.94×10^{-06}) and myocardial infarction (MI) (OR = 0.69
- [0.58-0.83], $p = 9.62 \times 10^{-05}$ (Figure 2). In total, this variant had PWS significant protective effect
- on 14 disease endpoints, all related to coronary atherosclerosis. The majority of these disease
- endpoints are highly overlapping and representing major coronary heart disease (CHD) event. For
- this variant, we did not detect other phenome-wide significant associations among the 2 861
- endpoints in our data. Risk-lowering effect of rs534125149 on CHD was replicated in Biobank
- Japan ^{22, 23} (BBJ) and the Estonian Biobank (EstBB) ²¹ (35 644 cases and 328 461 controls total: OR
- $239 = 0.754 [0.67-0.84], p = 5.41 \times 10^{-7}$). Association results for rs534125149 with CHD and MI across
- 240 different cohorts are shown in **Supplementary Figure 4**.
- 241



243

244 Figure 2: Phenome-wide association study (PheWAS) results for rs534125149. Total number of 245 tested endpoints is 2 861 (A complete list of endpoints analyzed and their definitions is available at https://www.finngen.fi/en/researchers/clinical-endpoints). The dashed line represents the phenome-246 wide significance threshold, multiple testing corrected by the number of endpoints = 0.05/2.861 =247 1.75×10^{-5} . All endpoints reaching that threshold are labelled in the figure. 248

249

Splice acceptor variant rs201988637 in MFGE8 250

- 251 In addition to inframe insertion rs53412514, we also identified a splice acceptor variant
- 252 (rs201988637) in *MFGE8* to have a protective effect on coronary atherosclerosis (OR = 0.72 [0.63-
- (0.83], p = 7.94×10^{-06}) and related endpoints. The splice acceptor variant had very similar PheWAS 253
- profile as the indel (Supplementary Figure 5) and furthermore the two variants had very similar 254
- protective effect sizes for the endpoints (Figure 3 and Supplementary Table 1). Similar to 255
- rs534125149, this variant is also highly enriched in Finland (37- fold compared to NFE), allele 256

- frequency in Finland being 0.6 %. Moreover, both the splice acceptor and the inframe insertion
- variants were enriched to Eastern Finland (Supplementary Figure 6).



259 260

Figure 3: Comparison of the effects (OR) of rs534125149 and rs201988637 for 14 endpoints with
 p-value < 1.75×10-5 (PWS) for rs534125149.95% confidence intervals represented as grey lines.



These two variants (rs534125149 and rs201988637) are in low linkage disequilibrium (LD, $r^2 =$

265 0.00015) and did not have any effect on the other variant's associations with coronary

atherosclerosis or MI (Table 3 and Supplementary Figure 7). This indicates that they both have

their own, independent protective effect against these endpoints.

268

270	Table 3: Results of the	conditional analysis on MI	and coronary atherosclerosis.
-----	-------------------------	----------------------------	-------------------------------

Dhonotyno	SNPID	Most severe	Original GWA	S results	Conditional results	
Phenotype	[cnr:position:ref:ait] (rsid)	consequence	OR [CI]	P-value	OR [CI]	P-value
Coronary	chr15:88901702:C:CTGT (rs534125149)	Inframe insertion	0.75 [0.71-0.81]	2.63×10 ⁻¹⁶	0.75 [0.70-0.80] ª	7.68×10 ⁻¹⁵ a
atherosclerosis	chr15:88899813:T:G (rs201988637)	Splice acceptor variant	0.72 [0.63-0.83]	7.94×10-6	0.73 [0.64-0.85] ^b	1.99×10 ^{-5 в}
Myocardial	chr15:88901702:C:CTGT (rs534125149)	Inframe insertion	0.74 [0.68-0.81]	1.95×10-11	0.79 [0.73-0.85] ª	1.92×10 ⁻¹⁰ a
strict	chr15:88899813:T:G (rs201988637)	Splice acceptor variant	0.69 [0.58-0.83]	9.62×10-5	0.71 [0.59-0.85] ^b	4.03×10 ⁻⁴ b

271

This table present the conditional analysis results for coronary atherosclerosis and MI (strict definition, only primary diagnoses accepted) where the association has been conditioned on rs534125149 and rs201988637

- 274 separately
- 275
- 276 a Conditional on rs201988637
- 277 ^b Conditional on rs534125149
- 278

279 Survival analysis

280 281

282 In addition to protection against coronary atherosclerosis and myocardial infarction, both the infame

insertion rs534125149 and splice acceptor variant rs201988637 showed also significant association

284 in survival analysis when analyzing survival time from birth to first diagnose of coronary

285 atherosclerosis (HR = 0.78 [0.74-0.93]), p = 1.67×10^{-17} and HR = 0.77 [0.69-0.88], p = 5.08×10^{-05} ,

respectively) and myocardial infarction (HR = 0.86 [0.80-0.93], p = 2.63×10^{-10} and HR = 0.72

287 [0.61-0.85], p = 8.16×10⁻⁰⁵). In addition, when combining the heterozygous and homozygous

carriers of both rs534125149 and rs201988637 together, carriers get the first diagnose significantly

289 later than non-carriers (HR = 0.81 [0.77-0.85], p = 6.4×10^{-16} for coronary atherosclerosis and HR =

290 0.78 [0.72-0.85], $p = 1.16 \times 10^{-11}$ for MI) (Figure 4).



292

Figure 4: Cumulative incidence plots for myocardial infarction. Red line represents carriers (homoor heterozygous) for either rs534125149 or rs201988637, and blue line represent non-carriers.
Dashed lines represent 95%- confidence intervals.

296

297 Associations with risk factors for CVD and coronary heart disease sub-types

298 We then tested for possible associations between the *MFGE8* variants and risk factors for CVD.

299 The splice acceptor variant rs201988637 was associated with pulse pressure in analyses across four

300 cohorts with pulse pressure measurements and variant rs201988637 available, with the risk

301 lowering allele associated with lower pulse pressure (p = 1.08×10^{-03} , β = -1.52 [-2.43- -0.61])

302 mmHg (Figure 5). In addition, rs534125149 was significantly associated with height, but further

analysis pointed this signal to be reflecting the association of a known association of ACAN with

height, located near *MFGE8* (Supplementary material, Supplementary Figure 8). No associations
with other risk factors were observed.

306

307 In the Corogene cohort (n = 4.896), rs534125149 significantly (p < 0.05) lowers the risk for acute

308 coronary syndrome and stable coronary heart disease (RR = 0.87 and 0.83, respectively) compared

309 to healthy controls, but not against other types of heart attack, further pointing to a specific risk-

310 lowering effect of *MFGE8* on ischemic heart diseases (Supplementary Figure 9).

311

312 Previously reported common variants near MFGE8

313 Previously, common intergenic variant (rs8042271) near MFGE8 has been reported to associate with coronary heart disease (CHD) risk^{3, 27}. We replicate this association (OR = 0.90, p = 3.69×10^{-10} for 314 315 coronary atherosclerosis) in FinnGen. LD between the common variant rs8042271 and the inframe 316 insertion rs534125149 is 0.154. The LD characteristics for all 3 variants in MFGE8 (rs534125149, rs201988637 and rs8042271) in FinnGen are in Supplementary Table 2. Common variant 317 318 rs8042271 was in the 95% credible set for MI with the causal probability of 0.003 but was not 319 included in the 95% credible sets for coronary atherosclerosis (Supplementary Table 3 and 320 Supplementary Table 4). The conditional analyses of all three MFGE8 variants showed that the 321 association of the previously reported common variant rs8042271 can be explained by the inframe 322 insertion variant rs534125149, but not vice versa, and that the association of the splice acceptor 323 variant rs201988637 is independent of both rs534125149 and rs8042271 (Supplementary Table 5).



326

327 Figure 5: Results for pulse pressure association across all cohorts with splice acceptor variant rs201988637 present. 328

329

Fine-mapping of the MFGE8 locus 330

331 In our fine-mapping analyses, MI had most probably one credible set (set of causal variants) of 32 332 variants with the highest posterior probability (posterior probability = 0.62), and coronary 333 atherosclerosis had two credible sets of 6 and 45 variants, respectively, with the highest posterior 334 probability (posterior probability = 0.74). For both MI and coronary atherosclerosis, rs534125149 335 had the highest probability of being causal (probability of being causal = 0.250 and 0.318, respectively) and was included in the first credible set (Supplementary Table 3, Supplementary 336 Table 4 and Supplementary Figure 10). Splice acceptor variant rs201988637 was not included in 337 338 the credible sets for either MI or coronary atherosclerosis, whereas previously reported common

variant rs8042271 was included in the credible set for MI with the probability of being causal = 0.003
(Supplementary Table 3).

341

342 Discussion

343 Here we show that a loss of function for MFGE8 leads to 28% lower risk of myocardial infarction 344 and reduces risk for other coronary atherosclerosis-related diseases. The effects are specific to 345 coronary heart disease events and no significant association was observed to other diseases in a 346 phenome-wide search, even if this can be due to lower statistical power in rare disease endpoints. 347 Loss-of-function of MFGE8 was also associated with lower pulse pressure, but not with blood lipids, 348 blood pressure or other known coronary heart disease risk factors. In addition to MFGE8, we report 349 three other novel loci associated with coronary atherosclerosis risk, and to our knowledge we report 350 the first CHD associated locus, FHL1, in chromosome X.

351

352 Our findings allow us to draw several conclusions. First, MFGE8 is a potential intervention target 353 with specific effects on coronary heart disease. Specific protective effect with the LoF in MFGE8 354 shows potential for efficacy of a treatment targeting MFGE8 protein or downstream products. 355 Second, the lack of risk elevation in other diseases provide evidence on the potential safety of the 356 intervention. Previously, the protective effect of loss-of-function variants have been reported for 357 example for PCSK9⁵ and APOC3⁶, and in phase I, II and III trials, inhibition of PCSK9 have led to 358 significantly decreased LDL-C levels, and in short-term trials, PCSK9 inhibitors have been well-359 tolerated and have had a low incidence of adverse effects.²⁸ Based on the phenome-wide association 360 profile for the loss-of-function variant, we hypothesize that inhibiting MFGE8 could lower the CHD 361 risk.

363 An association of loss-of-function of *MFGE8* with lower pulse pressure, a potential biomarker for 364 arterial stiffness ²⁹, are very much in line with previous studies on MFGE8 and the inflammatory 365 ageing process of the arteries, highlighting the possible role of MFGE8 in arterial ageing and 366 stiffness. The MFGE8 gene encodes Milk-fat globule-EGF 8 (MFGE8), or lactadherin, which is an 367 integrin-binding glycoprotein implicated in vascular smooth muscle cell (VSMC) proliferation and invasion, and the secretion of pro-inflammatory molecules ^{30, 31}. Lactadherin is known to play 368 important roles in several other biological processes, including apoptotic cell clearance and adaptive 369 370 immunity ³², which are known to contribute to the pathogenesis of ischemic stroke. Initially 371 lactadherin was identified as a bridging molecule between apoptotic cells and phagocytic 372 macrophages ³³⁻³⁵, but a growing evidence has indicated that it is a secreted inflammatory mediator 373 that orchestrates diverse cellular interactions involved in the pathogenesis of various diseases, 374 including vascular metabolic disorders and some tumors ³⁶⁻⁴⁰ and cancers, such as breast ^{38,41}, 375 bladder⁴², esophageal⁴³ and colorectal cancer ⁴⁴. Recently, not only has MFG-E8 expression emerged as a molecular hallmark of adverse cardiovascular remodeling with age ⁴⁵⁻⁴⁸, but MFG-E8 376 377 signaling has also been found to mediate the vascular outcomes of cellular and matrix responses to 378 the hostile stresses associated with hypertension, diabetes, and atherosclerosis ⁴⁹⁻⁵³.

379

380 Arterial inflammation and remodeling are linked to the pathogenesis of age-associated arterial 381 diseases, such as atherosclerosis. Recently, lactadherin has been identified as a novel local 382 biomarker for ageing arterial walls by high-throughput proteomic screening, and it has been shown 383 to also be an element of the arterial inflammatory signaling network ⁵⁴. The transcription, 384 translation, and signaling levels of MFG-E8 are increased in aged, atherosclerotic, hypertensive, 385 and diabetic arterial walls in vivo, as well as activated VSMCs and a subset of macrophages in 386 vitro. During aging, both MFG-E8 transcription and translation increase within the arterial walls 387 and hearts of various species, including rats, humans, and monkeys^{48, 55-57}, and MFG-E8 is markedly

388	up-regulated in rat aortic walls with ageing ⁴⁸ . High levels of MFG-E8 have also been detected
389	within endothelial cells, SMC, and macrophages of atherosclerotic aortae in both mice and
390	humans ^{53, 58} . Furthermore, in the advanced atherosclerotic plaques found in murine models,
391	decreased macrophage MFG-E8 levels are associated with an inhibition of apoptotic cell
392	engulfment, leading to the accumulation of cellular debris during the pathogenesis of
393	atherosclerosis. Lastly, lactadherin has shown tissue protection in various models of organ injury,
394	including suppression of inflammation and apoptosis in intestinal ischemia in mice ⁵⁹ , as well as
395	inducing recovery from ischemia by facilitating angiogenesis 60.
396	
397	Our study does, however, have a few limitations. First, our primary association results come from
398	Finnish population with considerable elevation in allele frequency in MFGE8 variants among Finns.
399	Therefore, the replication of the association in other populations has reduced statistical power.
400	However, there were enough carriers combined in Japanese, Estonian and UK samples to replicate
401	robustly both the protective association with coronary artery disease and for pulse pressure. Secondly,

although our data shows association with pulse pressure which has previously been linked to arterial
stiffness, the direct effect of the genetic variants on arterial stiffness and arterial aging needs further
evidence.

405

In conclusion, our results show that inhibiting production of lactadherin could reduce the risk for coronary atherosclerosis substantially and thus present *MFGE8* as a potential therapeutical target for atherosclerotic cardiovascular disease. Our study also highlights the potential of FinnGen, as a largescale biobank study in isolated population to identify high-impact variants either very rare or absent in other populations.

411

412

References

- 413 1. Kessler, T., Erdmann, J. & Schunkert, H. Genetics of coronary artery disease and myocardial
 414 infarction-2013. *Curr. Cardiol. Rep.* 15, 368 (2013).
- 415 2. O'Donnell, C. J. & Nabel, E. G. Genomics of cardiovascular disease. *N. Engl. J. Med.* **365**, 2098-416 2109 (2011).
- 417 3. Nikpay, M. *et al.* A comprehensive 1000 Genomes–based genome-wide association meta-418 analysis of coronary artery disease. *Nat. Genet.* **47**, 1121 (2015).
- 4. Lim, E. T. *et al.* Distribution and medical impact of loss-of-function variants in the Finnish
 founder population. *PLoS genetics* **10** (2014).
- 5. Cohen, J. C., Boerwinkle, E., Mosley Jr, T. H. & Hobbs, H. H. Sequence variations in PCSK9,
 low LDL, and protection against coronary heart disease. *N. Engl. J. Med.* 354, 1264-1272 (2006).
- 423 6. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and
- 424 Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl.
- 425 J. Med. **371**, 22-31 (2014).
- 426 7. Dewey, F. E. *et al.* Inactivating variants in ANGPTL4 and risk of coronary artery disease. *N.*427 *Engl. J. Med.* **374**, 1123-1133 (2016).
- 428 8. Libby, P. et al. Lewis EF. Atherosclerosis.Nature reviews Disease primers 5, 56 (2019).
- 429 9. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456
 430 humans. *Nature* 581, 434-443 (2020).
- 431 10. Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness in
 432 large-scale genetic association studies. *Nat. Genet.* 50, 1335-1341 (2018).
- 433 11. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association
 434 studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* 47, D1005-D1012 (2018).
- 435 12. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genome-wide
 436 association studies. *Bioinformatics* 32, 1493-1501 (2016).
- 437 13. Vaara, S. et al. Cohort profile: the Corogene study. Int. J. Epidemiol. 41, 1265-1271 (2012).
- 438 14. Dey, R. *et al.* An efficient and accurate frailty model approach for genome-wide survival
 439 association analysis controlling for population structure and relatedness in large-scale biobanks.
 440 *bioRxiv* (2020).
- 441 15. Breslow, N. E. & Clayton, D. G. Approximate inference in generalized linear mixed models.
 442 *Journal of the American statistical Association* 88, 9-25 (1993).
- 16. Chen, H. *et al.* Control for population structure and relatedness for binary traits in genetic
 association studies via logistic mixed models. *The American Journal of Human Genetics* 98, 653666 (2016).

- 446 17. Borodulin, K. *et al.* Forty-year trends in cardiovascular risk factors in Finland. *The European*447 *Journal of Public Health* 25, 539-546 (2014).
- 448 18. Widen, E. et al. Communicating polygenic and non-genetic risk for atherosclerotic
- 449 cardiovascular disease-An observational follow-up study. *medRxiv* (2020).
- 450 19. Raitakari, O. T. *et al.* Cohort profile: the cardiovascular risk in Young Finns Study. *Int. J.*451 *Epidemiol.* 37, 1220-1226 (2008).
- 452 20. Mitt, M. *et al.* Improved imputation accuracy of rare and low-frequency variants using
- population-specific high-coverage WGS-based imputation reference panel. *European Journal of Human Genetics* 25, 869 (2017).
- 455 21. Leitsalu, L. *et al.* Cohort profile: Estonian biobank of the Estonian genome center, university of
 456 Tartu. *Int. J. Epidemiol.* 44, 1137-1147 (2015).
- 457 22. Nagai, A. *et al.* Overview of the BioBank Japan Project: study design and profile. *Journal of*458 *epidemiology* 27, S2-S8 (2017).
- 459 23. Sakaue, S. *et al.* A global atlas of genetic associations of 220 deep phenotypes. *medRxiv*,
 460 2020.10. 23.20213652 (2021).
- 461 24. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature*462 562, 203 (2018).
- 463 25. Cooper, H., Hedges, L. V. & Valentine, J. C. in *The handbook of research synthesis and meta-*464 *analysis* (Russell Sage Foundation, 2019).
- 465 26. Evangelou, E. & Ioannidis, J. P. Meta-analysis methods for genome-wide association studies
 466 and beyond. *Nature Reviews Genetics* 14, 379-389 (2013).
- 467 27. Soubeyrand, S. *et al.* Regulation of MFGE8 by the intergenic coronary artery disease locus on
 468 15q26. 1. *Atherosclerosis* 284, 11-17 (2019).
- 28. Dadu, R. T. & Ballantyne, C. M. Lipid lowering with PCSK9 inhibitors. *Nature Reviews Cardiology* 11, 563 (2014).
- 471 29. Benetos, A. et al. Mortality and cardiovascular events are best predicted by low
- 472 central/peripheral pulse pressure amplification but not by high blood pressure levels in elderly
- 473 nursing home subjects: the PARTAGE (Predictive Values of Blood Pressure and Arterial Stiffness
- 474 in Institutionalized Very Aged Population) study. J. Am. Coll. Cardiol. 60, 1503-1511 (2012).
- 30. Oshima, K. *et al.* Lactation-Dependent Expression of an mRNA Splice Variant with an Exon for
 a MultiplyO-Glycosylated Domain of Mouse Milk Fat Globule Glycoprotein MFG-E8. *Biochem*. *Biophys. Res. Commun.* 254, 522-528 (1999).
- 478 31. Aoki, N. *et al.* Immunologically cross-reactive 57 kDa and 53 kDa glycoprotein antigens of
 479 bovine milk fat globule membrane: isoforms with different N-linked sugar chains and differential
 480 glycosylation at early stages of lactation. *Biochimica et Biophysica Acta (BBA)-General Subjects*
- 481 **1200**, 227-234 (1994).

- 482 32. Deroide, N. *et al.* MFGE8 inhibits inflammasome-induced IL-1β production and limits
 483 postischemic cerebral injury. *J. Clin. Invest.* **123**, 1176-1181 (2013).
- 484 33. Hanayama, R. *et al.* Identification of a factor that links apoptotic cells to phagocytes. *Nature*485 417, 182-187 (2002).
- 486 34. Hanayama, R. *et al.* Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8487 deficient mice. *Science* 304, 1147-1150 (2004).
- 488 35. Yoshida, H. *et al.* Phosphatidylserine-dependent engulfment by macrophages of nuclei from
 489 erythroid precursor cells. *Nature* 437, 754-758 (2005).
- 36. Tahara, H. *et al.* Emerging concepts in biomarker discovery; the US-Japan Workshop on
 Immunological Molecular Markers in Oncology. *Journal of Translational Medicine* 7, 1-25 (2009).
- 37. Neutzner, M. *et al.* MFG-E8/lactadherin promotes tumor growth in an angiogenesis-dependent
 transgenic mouse model of multistage carcinogenesis. *Cancer Res.* 67, 6777-6785 (2007).
- 494 38. TAYLOR, M. R., COUTO, J. R., SCALLAN, C. D., CERIANI, R. L. & PETERSON, J. A.
- Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and
 breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion. *DNA Cell Biol.* 16, 861869 (1997).
- 39. Jinushi, M. *et al.* Milk fat globule EGF-8 promotes melanoma progression through coordinated
 Akt and twist signaling in the tumor microenvironment. *Cancer Res.* 68, 8889-8898 (2008).
- 40. Raymond, A., Ensslin, M. A. & Shur, B. D. SED1/MFG-E8: a bi-motif protein that orchestrates
 diverse cellular interactions. *J. Cell. Biochem.* 106, 957-966 (2009).
- 502 41. Yu, L. *et al.* MFG-E8 overexpression is associated with poor prognosis in breast cancer 503 patients. *Pathology-Research and Practice* **215**, 490-498 (2019).
- 42. Sugano, G. *et al.* Milk fat globule—epidermal growth factor—factor VIII (MFGE8)/lactadherin
 promotes bladder tumor development. *Oncogene* 30, 642-653 (2011).
- 43. Kanemura, T. *et al.* Immunoregulatory influence of abundant MFG-E8 expression by esophageal cancer treated with chemotherapy. *Cancer science* **109**, 3393-3402 (2018).
- 44. Jia, M. *et al.* Prognostic correlation between MFG-E8 expression level and colorectal Cancer.
 Arch. Med. Res. 48, 270-275 (2017).
- 45. Wang, M., Khazan, B. & G Lakatta, E. Central arterial aging and angiotensin II signaling. *Current hypertension reviews* 6, 266-281 (2010).
- 46. Wang, M., Monticone, R. E. & Lakatta, E. G. Arterial aging: a journey into subclinical arterial
 disease. *Curr. Opin. Nephrol. Hypertens.* 19, 201 (2010).
- 514 47. Ortiz, A. *et al.* Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis.
 515 *Nature reviews Nephrology* 8, 141 (2012).

- 516 48. Fu, Z. *et al.* Milk fat globule protein epidermal growth factor-8: a pivotal relay element within
- 517 the angiotensin II and monocyte chemoattractant protein-1 signaling cascade mediating vascular
- 518 smooth muscle cells invasion. *Circ. Res.* **104**, 1337-1346 (2009).
- 519 49. Bagnato, C. et al. Proteomics analysis of human coronary atherosclerotic plaque: a feasibility
- study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry.
 Molecular & Cellular Proteomics 6, 1088-1102 (2007).
- 522 50. Li, X. *et al.* Proteomics approach to study the mechanism of action of grape seed
- proanthocyanidin extracts on arterial remodeling in diabetic rats. *Int. J. Mol. Med.* 25, 237-248
 (2010).
- 525 51. Strøm, C. C. *et al.* Identification of a core set of genes that signifies pathways underlying 526 cardiac hypertrophy. *Comp. Funct. Genomics* **5**, 459-470 (2004).
- 527 52. Lin, Y. *et al.* Comparative proteomic analysis of rat aorta in a subtotal nephrectomy model.
 528 *Proteomics* 10, 2429-2443 (2010).
- 529 53. Ait-Oufella, H. et al. CLINICAL PERSPECTIVE. Circulation 115, 2168-2177 (2007).

530 54. Wang, M., H Wang, H. & G Lakatta, E. Milk fat globule epidermal growth factor VIII signaling
531 in arterial wall remodeling. *Current vascular pharmacology* 11, 768-776 (2013).

- 55. Peng, S., Glennert, J. & Westermark, P. Medin-amyloid: a recently characterized age-associated
 arterial amyloid form affects mainly arteries in the upper part of the body. *Amyloid* 12, 96-102
 (2005).
- 535 56. Peng, S. *et al.* Medin and medin-amyloid in ageing inflamed and non-inflamed temporal
 536 arteries. *The Journal of Pathology: A Journal of the Pathological Society of Great Britain and*537 *Ireland* 196, 91-96 (2002).
- 538 57. Grant, J. E. *et al.* Quantification of protein expression changes in the aging left ventricle of 539 Rattus norvegicus. *Journal of proteome research* **8**, 4252-4263 (2009).
- 540 58. Bagnato, C. *et al.* Proteomics analysis of human coronary atherosclerotic plaque: a feasibility 541 study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry.
- 542 Molecular & Cellular Proteomics 6, 1088-1102 (2007).
- 543 59. Cheyuo, C. *et al.* Recombinant human MFG-E8 attenuates cerebral ischemic injury: its role in 544 anti-inflammation and anti-apoptosis. *Neuropharmacology* **62**, 890-900 (2012).
- 60. Silvestre, J. *et al.* Lactadherin promotes VEGF-dependent neovascularization. *Nat. Med.* 11,
 499-506 (2005).
- 547

548 Acknowledgements

550 We would like to thank all participants of all study cohorts for their generous participation. We also 551 want to thank Dr. Kaoru Ito at RIKEN Center for Integrative Medical Sciences for supporting the 552 study. This work was supported by the Academy of Finland Center of Excellence in Complex Disease 553 Genetics (Grant No 312062 and 336820 to S.R.), the Finnish Foundation for Cardiovascular 554 Research, the Sigrid Juselius Foundation, University of Helsinki HiLIFE Fellow, Grand Challenge 555 grants and Horizon 2020 Research and Innovation Programme (grant number 101016775 "INTERVENE" to S.R.), Academy of Finland grant number 331671 to N.M., the European Union 556 557 through the European Regional Development Fund (Project No. 2014-2020.4.01.16-0125 to L.M.), 558 the Estonian Research Council grant PRG184 [to L.M.] and the Doctoral Programme in Population 559 Health, University of Helsinki [to S.E.R.].

560

The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 561 562 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA 563 Inc., Celgene Corporation, Celgene International II Sarl, Genentech Inc., Merck Sharp & Dohme 564 Corp, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, and Novartis AG. Following biobanks are 565 566 acknowledged for deliverig biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), 567 THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank 568 Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-569 Borealis-briefly-in-English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-570 US/Research and development/Finnish Clinical Biobank Tampere), Biobank of Eastern Finland 571 (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-572 FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) Terveystalo 573 and Biobank

574	(www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All Finnish Biobanks are		
575	members of BBMRI.fi infrastructure (www.bbmri.fi) and FinBB (https://finbb.fi/).		
576			
577	Estonian Biobanl	k research team	
578	Tõnu Esko,		
579	Andres Metspalu,		
580	Reedik Mägi,		
581	Mari Nelis		
582			
583	Contributors of F	FinnGen	
584	Steering Committee		
585	Aarno Palotie Institu	te for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland	
586	Mark Daly Institu	te for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland	
587			
588	Pharmaceutical compa	anies	
589	Bridget Riley-Gills	Abbvie, Chicago, IL, United States	
590	Howard Jacob	Abbvie, Chicago, IL, United States	
591	Dirk Paul	Astra Zeneca, Cambridge, United Kingdom	
592	Heiko Runz	Biogen, Cambridge, MA, United States	
593	Sally John	Biogen, Cambridge, MA, United States	
594	Robert Plenge	Celgene, Summit, NJ, United States/Bristol Myers Squibb, New York, NY, United States	
595	Mark McCarthy	Genentech, San Francisco, CA, United States	
596	Julie Hunkapiller	Genentech, San Francisco, CA, United States	
597	Meg Ehm	GlaxoSmithKline, Brentford, United Kingdom	
598	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom	
599	Caroline Fox	Merck, Kenilworth, NJ, United States	
600	Anders Mälarstig	Pfizer, New York, NY, United States	
601	Katherine Klinger	Sanofi, Paris, France	
602	Deepak Raipal	Sanofi, Paris, France	

603	Tim Behrens	Maze Therapeutics, San Francisco, CA, United States
604	Robert Yang	Janssen Biotech, Beerse, Belgium
605	Richard Siegel	Novartis, Basel, Switzerland
606	University of Helsinki	& Biobanks
607	Tomi Mäkelä	HiLIFE, University of Helsinki, Finland, Finland
608	Jaakko Kaprio	Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland, Finland
609	Petri Virolainen	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku,
610	Finland	
611	Antti Hakanen	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku,
612	Finland	
613	Terhi Kilpi	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
614	Markus Perola	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
615	Jukka Partanen	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank,
616	Helsinki, Finland	
617	Anne Pitkäranta	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,
618	Helsinki	
619	Juhani Junttila	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
620	District, Oulu, Finland	
621	Raisa Serpi	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
622	District, Oulu, Finland	
623	Tarja Laitinen	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,
624	Tampere, Finland	
625	Johanna Mäkelä	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,
626	Tampere, Finland	
627	Veli-Matti Kosma	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,
628	Kuopio, Finland	
629	Urho Kujala	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,
630	Jyväskylä, Finland	
631		
632	Other Experts/ Non-Vo	oting Members

- 633 Outi Tuovila Business Finland, Helsinki, Finland
- 634 Raimo Pakkanen Business Finland, Helsinki, Finland
- 635
- 636 Scientific Committee

637 Pharmaceutical companies

638	Jeffrey Waring	Abbvie, Chicago, IL, United States
639	Ali Abbasi	Abbvie, Chicago, IL, United States
640	Mengzhen Liu	Abbvie, Chicago, IL, United States
641	Ioanna Tachmazidou	Astra Zeneca, Cambridge, United Kingdom
642	Chia-Yen Chen	Biogen, Cambridge, MA, United States
643	Heiko Runz	Biogen, Cambridge, MA, United States
644	Shameek Biswas	Celgene, Summit, NJ, United States/Bristol Myers Squibb, New York, NY, United States
645	Julie Hunkapiller	Genentech, San Francisco, CA, United States
646	Meg Ehm	GlaxoSmithKline, Brentford, United Kingdom
647	Neha Raghavan	Merck, Kenilworth, NJ, United States
648	Adriana Huertas-Vazquez	Merck, Kenilworth, NJ, United States
649	Anders Mälarstig	Pfizer, New York, NY, United States
650	Xinli Hu	Pfizer, New York, NY, United States
651	Katherine Klinger	Sanofi, Paris, France
652	Matthias Gossel	Sanofi, Paris, France
653	Robert Graham	Maze Therapeutics, San Francisco, CA, United States
654	Tim Behrens	Maze Therapeutics, San Francisco, CA, United States
655	Beryl Cummings	Maze Therapeutics, San Francisco, CA, United States
656	Wilco Fleuren	Janssen Biotech, Beerse, Belgium
657	Dawn Waterworth	Janssen Biotech, Beerse, Belgium
658	Nicole Renaud	Novartis, Basel, Switzerland
659	Ma´en Obeidat	Novartis, Basel, Switzerland
660		
661	University of Helsinki &	Biobanks
662	Samuli Ripatti	Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland

663	Johanna Schleutker	Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland
664	Markus Perola	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
665	Mikko Arvas	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank,
666	Helsinki, Finland	
667	Olli Carpén	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,
668	Helsinki	
669	Reetta Hinttala	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
670	District, Oulu, Finland	
671	Johannes Kettunen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
672	District, Oulu, Finland	
673	Johanna Mäkelä	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,
674	Tampere, Finland	
675	Arto Mannermaa	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital
676	District, Kuopio, Finland	
677	Jari Laukkanen	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,
678	Jyväskylä, Finland	
679	Urho Kujala	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,
680	Jyväskylä, Finland	
681		
682	Clinical Groups	
683	Neurology Group	
684	Reetta Kälviäinen	Northern Savo Hospital District, Kuopio, Finland
685	Valtteri Julkunen	Northern Savo Hospital District, Kuopio, Finland
686	Hilkka Soininen	Northern Savo Hospital District, Kuopio, Finland
687	Anne Remes	Northern Ostrobothnia Hospital District, Oulu, Finland
688	Mikko Hiltunen	Northern Savo Hospital District, Kuopio, Finland
689	Jukka Peltola	Pirkanmaa Hospital District, Tampere, Finland
690	Pentti Tienari	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
691	Juha Rinne	Hospital District of Southwest Finland, Turku, Finland
692	Roosa Kallionpää	Hospital District of Southwest Finland, Turku, Finland

693	Ali Abbasi	Abbvie, Chicago, IL, United States
694	Adam Ziemann	Abbvie, Chicago, IL, United States
695	Jeffrey Waring	Abbvie, Chicago, IL, United States
696	Sahar Esmaeeli	Abbvie, Chicago, IL, United States
697	Nizar Smaoui	Abbvie, Chicago, IL, United States
698	Anne Lehtonen	Abbvie, Chicago, IL, United States
699	Susan Eaton	Biogen, Cambridge, MA, United States
700	Heiko Runz	Biogen, Cambridge, MA, United States
701	Sanni Lahdenperä	Biogen, Cambridge, MA, United States
702	Janet van Adelsberg	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
703	Shameek Biswas	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
704	Julie Hunkapiller	Genentech, San Francisco, CA, United States
705	Natalie Bowers	Genentech, San Francisco, CA, United States
706	Edmond Teng	Genentech, San Francisco, CA, United States
707	Sarah Pendergrass	Genentech, San Francisco, CA, United States
708	Onuralp Soylemez	Merck, Kenilworth, NJ, United States
709	Kari Linden	Pfizer, New York, NY, United States
710	Fanli Xu	GlaxoSmithKline, Brentford, United Kingdom
711	David Pulford	GlaxoSmithKline, Brentford, United Kingdom
712	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
713	Laura Addis	GlaxoSmithKline, Brentford, United Kingdom
714	John Eicher	GlaxoSmithKline, Brentford, United Kingdom
715	Minna Raivio	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
716	Sarah Pendergrass	Genentech, San Francisco, CA, United States
717	Beryl Cummings	Maze Therapeutics, San Francisco, CA, United States
718	Juulia Partanen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
719		
720	Gastroenterology Group	
721	Martti Färkkilä	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
722	Jukka Koskela	Hospital District of Helsinki and Uusimaa, Helsinki, Finland

723	Sampsa Pikkarainen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
724	Airi Jussila	Pirkanmaa Hospital District, Tampere, Finland
725	Katri Kaukinen	Pirkanmaa Hospital District, Tampere, Finland
726	Timo Blomster	Northern Ostrobothnia Hospital District, Oulu, Finland
727	Mikko Kiviniemi	Northern Savo Hospital District, Kuopio, Finland
728	Markku Voutilainen	Hospital District of Southwest Finland, Turku, Finland
729	Ali Abbasi	Abbvie, Chicago, IL, United States
730	Graham Heap	Abbvie, Chicago, IL, United States
731	Jeffrey Waring	Abbvie, Chicago, IL, United States
732	Nizar Smaoui	Abbvie, Chicago, IL, United States
733	Fedik Rahimov	Abbvie, Chicago, IL, United States
734	Anne Lehtonen	Abbvie, Chicago, IL, United States
735	Keith Usiskin	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
736	Tim Lu	Genentech, San Francisco, CA, United States
737	Natalie Bowers	Genentech, San Francisco, CA, United States
738	Danny Oh	Genentech, San Francisco, CA, United States
739	Sarah Pendergrass	Genentech, San Francisco, CA, United States
740	Kirsi Kalpala	Pfizer, New York, NY, United States
741	Melissa Miller	Pfizer, New York, NY, United States
742	Xinli Hu	Pfizer, New York, NY, United States
743	Linda McCarthy	GlaxoSmithKline, Brentford, United Kingdom
744	Onuralp Soylemez	Merck, Kenilworth, NJ, United States
745	Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
746		
747	Rheumatology Group	
748	Kari Eklund	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
749	Antti Palomäki	Hospital District of Southwest Finland, Turku, Finland
750	Pia Isomäki	Pirkanmaa Hospital District, Tampere, Finland
751	Laura Pirilä	Hospital District of Southwest Finland, Turku, Finland
752	Oili Kaipiainen-Seppänen	Northern Savo Hospital District, Kuopio, Finland

753	Johanna Huhtakangas	Northern Ostrobothnia Hospital District, Oulu, Finland
754	Ali Abbasi	Abbvie, Chicago, IL, United States
755	Jeffrey Waring	Abbvie, Chicago, IL, United States
756	Fedik Rahimov	Abbvie, Chicago, IL, United States
757	Apinya Lertratanakul	Abbvie, Chicago, IL, United States
758	Nizar Smaoui	Abbvie, Chicago, IL, United States
759	Anne Lehtonen	Abbvie, Chicago, IL, United States
760	David Close	Astra Zeneca, Cambridge, United Kingdom
761	Marla Hochfeld	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
762	Natalie Bowers	Genentech, San Francisco, CA, United States
763	Sarah Pendergrass	Genentech, San Francisco, CA, United States
764	Onuralp Soylemez	Merck, Kenilworth, NJ, United States
765	Kirsi Kalpala	Pfizer, New York, NY, United States
766	Nan Bing	Pfizer, New York, NY, United States
767	Xinli Hu	Pfizer, New York, NY, United States
768	Jorge Esparza Gordillo	GlaxoSmithKline, Brentford, United Kingdom
769	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
770	Dawn Waterworth	Janssen Biotech, Beerse, Belgium
771	Nina Mars	Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland
772		
773	Pulmonology Group	
774	Tarja Laitinen	Pirkanmaa Hospital District, Tampere, Finland
775	Margit Pelkonen	Northern Savo Hospital District, Kuopio, Finland
776	Paula Kauppi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
777	Hannu Kankaanranta	Pirkanmaa Hospital District, Tampere, Finland
778	Terttu Harju	Northern Ostrobothnia Hospital District, Oulu, Finland
779	Riitta Lahesmaa	Hospital District of Southwest Finland, Turku, Finland
780	Nizar Smaoui	Abbvie, Chicago, IL, United States
781	Alex Mackay	Astra Zeneca, Cambridge, United Kingdom
782	Glenda Lassi	Astra Zeneca, Cambridge, United Kingdom

783	Susan Eaton	Biogen, Cambridge, MA, United States
784	Steven Greenberg	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
785	Hubert Chen	Genentech, San Francisco, CA, United States
786	Sarah Pendergrass	Genentech, San Francisco, CA, United States
787	Natalie Bowers	Genentech, San Francisco, CA, United States
788	Joanna Betts	GlaxoSmithKline, Brentford, United Kingdom
789	Soumitra Ghosh	GlaxoSmithKline, Brentford, United Kingdom
790	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
791	Rajashree Mishra	GlaxoSmithKline, Brentford, United Kingdom
792	Sina Rüeger	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
793		
794	Cardiometabolic Disea	ses Group
795	Teemu Niiranen	The National Institute of Health and Welfare Helsinki, Finland
796	Felix Vaura	The National Institute of Health and Welfare Helsinki, Finland
797	Veikko Salomaa	The National Institute of Health and Welfare Helsinki, Finland
798	Markus Juonala	Hospital District of Southwest Finland, Turku, Finland
799	Kaj Metsärinne	Hospital District of Southwest Finland, Turku, Finland
800	Mika Kähönen	Pirkanmaa Hospital District, Tampere, Finland
801	Juhani Junttila	Northern Ostrobothnia Hospital District, Oulu, Finland
802	Markku Laakso	Northern Savo Hospital District, Kuopio, Finland
803	Jussi Pihlajamäki	Northern Savo Hospital District, Kuopio, Finland
804	Daniel Gordin	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
805	Juha Sinisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
806	Marja-Riitta Taskinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
807	Tiinamaija Tuomi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
808	Jari Laukkanen	Central Finland Health Care District, Jyväskylä, Finland
809	Benjamin Challis	Astra Zeneca, Cambridge, United Kingdom
810	Dirk Paul	Astra Zeneca, Cambridge, United Kingdom
811	Julie Hunkapiller	Genentech, San Francisco, CA, United States
812	Natalie Bowers	Genentech, San Francisco, CA, United States

813	Sarah Pendergrass	Genentech, San Francisco, CA, United States
814	Onuralp Soylemez	Merck, Kenilworth, NJ, United States
815	Jaakko Parkkinen	Pfizer, New York, NY, United States
816	Melissa Miller	Pfizer, New York, NY, United States
817	Russell Miller	Pfizer, New York, NY, United States
818	Audrey Chu	GlaxoSmithKline, Brentford, United Kingdom
819	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
820	Keith Usiskin	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
821	Amanda Elliott	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
822	Institute, Cambridge, MA	, United States
823	Joel Rämö	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
824	Samuli Ripatti	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
825	Mary Pat Reeve	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
826	Sanni Ruotsalainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
827		
828	Oncology Group	
829	Tuomo Meretoja	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
830	Heikki Joensuu	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
831	Olli Carpén	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
832	Lauri Aaltonen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
833	Johanna Mattson	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
834	Annika Auranen	Pirkanmaa Hospital District, Tampere, Finland
835	Peeter Karihtala	Northern Ostrobothnia Hospital District, Oulu, Finland
836	Saila Kauppila	Northern Ostrobothnia Hospital District, Oulu, Finland
837	Päivi Auvinen	Northern Savo Hospital District, Kuopio, Finland
838	Klaus Elenius	Hospital District of Southwest Finland, Turku, Finland
839	Johanna Schleutker	Hospital District of Southwest Finland, Turku, Finland
840	Relja Popovic	Abbvie, Chicago, IL, United States
841	Jeffrey Waring	Abbvie, Chicago, IL, United States
842	Bridget Riley-Gillis	Abbvie, Chicago, IL, United States

843	Anne Lehtonen	Abbvie, Chicago, IL, United States
844	Jennifer Schutzman	Genentech, San Francisco, CA, United States
845	Julie Hunkapiller	Genentech, San Francisco, CA, United States
846	Natalie Bowers	Genentech, San Francisco, CA, United States
847	Sarah Pendergrass	Genentech, San Francisco, CA, United States
848	Andrey Loboda	Merck, Kenilworth, NJ, United States
849	Aparna Chhibber	Merck, Kenilworth, NJ, United States
850	Heli Lehtonen	Pfizer, New York, NY, United States
851	Stefan McDonough	Pfizer, New York, NY, United States
852	Marika Crohns	Sanofi, Paris, France
853	Sauli Vuoti	Sanofi, Paris, France
854	Diptee Kulkarni	GlaxoSmithKline, Brentford, United Kingdom
855	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
856	Esa Pitkänen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
857	Nina Mars	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
858	Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
859		
860	Opthalmology Group	
861	Kai Kaarniranta	Northern Savo Hospital District, Kuopio, Finland
862	Joni A Turunen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
863	Terhi Ollila	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
864	Sanna Seitsonen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
865	Hannu Uusitalo	Pirkanmaa Hospital District, Tampere, Finland
866	Vesa Aaltonen	Hospital District of Southwest Finland, Turku, Finland
867	Hannele Uusitalo-Järviner	n Pirkanmaa Hospital District, Tampere, Finland
868	Marja Luodonpää	Northern Ostrobothnia Hospital District, Oulu, Finland
869	Nina Hautala	Northern Ostrobothnia Hospital District, Oulu, Finland
870	Mengzhen Liu	Abbvie, Chicago, IL, United States
871	Heiko Runz	Biogen, Cambridge, MA, United States
872	Stephanie Loomis	Biogen, Cambridge, MA, United States

873	Erich Strauss	Genentech, San Francisco, CA, United States
874	Natalie Bowers	Genentech, San Francisco, CA, United States
875	Hao Chen	Genentech, San Francisco, CA, United States
876	Sarah Pendergrass	Genentech, San Francisco, CA, United States
877	Anna Podgornaia	Merck, Kenilworth, NJ, United States
878	Juha Karjalainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
879	Institute, Cambridge, MA	, United States
880	Esa Pitkänen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
881		
882	Dermatology Group	
883	Kaisa Tasanen	Northern Ostrobothnia Hospital District, Oulu, Finland
884	Laura Huilaja	Northern Ostrobothnia Hospital District, Oulu, Finland
885	Katariina Hannula-Jouppi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
886	Teea Salmi	Pirkanmaa Hospital District, Tampere, Finland
887	Sirkku Peltonen	Hospital District of Southwest Finland, Turku, Finland
888	Leena Koulu	Hospital District of Southwest Finland, Turku, Finland
889	Kirsi Kalpala	Pfizer, New York, NY, United States
890	Ying Wu	Pfizer, New York, NY, United States
891	David Choy	Genentech, San Francisco, CA, United States
892	Sarah Pendergrass	Genentech, San Francisco, CA, United States
893	Nizar Smaoui	Abbvie, Chicago, IL, United States
894	Fedik Rahimov	Abbvie, Chicago, IL, United States
895	Anne Lehtonen	Abbvie, Chicago, IL, United States
896	Dawn Waterworth	Janssen Biotech, Beerse, Belgium
897		
898	Odontology Group	
899	Pirkko Pussinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
900	Aino Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
901	Tuula Salo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
902	David Rice	Hospital District of Helsinki and Uusimaa, Helsinki, Finland

903	Pekka Nieminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
904	Ulla Palotie	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
905	Juha Sinisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
906	Maria Siponen	Northern Savo Hospital District, Kuopio, Finland
907	Liisa Suominen	Northern Savo Hospital District, Kuopio, Finland
908	Päivi Mäntylä	Northern Savo Hospital District, Kuopio, Finland
909	Ulvi Gursoy	Hospital District of Southwest Finland, Turku, Finland
910	Vuokko Anttonen	Northern Ostrobothnia Hospital District, Oulu, Finland
911	Kirsi Sipilä	Northern Ostrobothnia Hospital District, Oulu, Finland
912	Sarah Pendergrass	Genentech, San Francisco, CA, United States
913		
914	Women's Health and Re	eproduction Group
915	Hannele Laivuori	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
916	Venla Kurra	Pirkanmaa Hospital District, Tampere, Finland
917	Oskari Heikinheimo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
918	Ilkka Kalliala	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
919	Laura Kotaniemi-Talonen	Pirkanmaa Hospital District, Tampere, Finland
920	Kari Nieminen	Pirkanmaa Hospital District, Tampere, Finland
921	Päivi Polo	Hospital District of Southwest Finland, Turku, Finland
922	Kaarin Mäkikallio	Hospital District of Southwest Finland, Turku, Finland
923	Eeva Ekholm	Hospital District of Southwest Finland, Turku, Finland
924	Marja Vääräsmäki	Northern Ostrobothnia Hospital District, Oulu, Finland
925	Outi Uimari	Northern Ostrobothnia Hospital District, Oulu, Finland
926	Laure Morin-Papunen	Northern Ostrobothnia Hospital District, Oulu, Finland
927	Marjo Tuppurainen	Northern Savo Hospital District, Kuopio, Finland
928	Katja Kivinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
929	Elisabeth Widen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
930	Taru Tukiainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
931	Mary Pat Reeve	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
932	Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

933	Liu Aoxing	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
934	Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland
935	Niko Välimäki	University of Helsinki, Helsinki, Finland
936	Lauri Aaltonen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
937	Johannes Kettunen	Northern Ostrobothnia Hospital District, Oulu, Finland
938	Mikko Arvas	Finnish Red Cross Blood Service, Helsinki, Finland
939	Jeffrey Waring	Abbvie, Chicago, IL, United States
940	Bridget Riley-Gillis	Abbvie, Chicago, IL, United States
941	Mengzhen Liu	Abbvie, Chicago, IL, United States
942	Janet Kumar	GlaxoSmithKline, Brentford, United Kingdom
943	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
944	Andrea Ganna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
945	Sarah Pendergrass	Genentech, San Francisco, CA, United States
946 947	FinnGen Analysis working group	
948	Justin Wade Davis	Abbvie, Chicago, IL, United States
949	Bridget Riley-Gillis	Abbvie, Chicago, IL, United States
950	Danjuma Quarless	Abbvie, Chicago, IL, United States
951	Fedik Rahimov	Abbvie, Chicago, IL, United States
952	Sahar Esmaeeli	Abbvie, Chicago, IL, United States
953	Slavé Petrovski	Astra Zeneca, Cambridge, United Kingdom
954	Eleonor Wigmore	Astra Zeneca, Cambridge, United Kingdom
955	Adele Mitchell	Biogen, Cambridge, MA, United States
956	Benjamin Sun	Biogen, Cambridge, MA, United States
957	Ellen Tsai	Biogen, Cambridge, MA, United States
958	Denis Baird	Biogen, Cambridge, MA, United States
959	Paola Bronson	Biogen, Cambridge, MA, United States
960	Ruoyu Tian	Biogen, Cambridge, MA, United States
961	Stephanie Loomis	Biogen, Cambridge, MA, United States
962	Yunfeng Huang	Biogen, Cambridge, MA, United States
963	Joseph Maranville	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States

964	Shameek Biswas	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
965	Elmutaz Mohammed	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
966	Samir Wadhawan	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
967	Erika Kvikstad	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
968	Minal Caliskan	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
969	Diana Chang	Genentech, San Francisco, CA, United States
970	Julie Hunkapiller	Genentech, San Francisco, CA, United States
971	Tushar Bhangale	Genentech, San Francisco, CA, United States
972	Natalie Bowers	Genentech, San Francisco, CA, United States
973	Sarah Pendergrass	Genentech, San Francisco, CA, United States
974	Kirill Shkura	Merck, Kenilworth, NJ, United States
975	Victor Neduva	Merck, Kenilworth, NJ, United States
976	Xing Chen	Pfizer, New York, NY, United States
977	Åsa Hedman	Pfizer, New York, NY, United States
978	Karen S King	GlaxoSmithKline, Brentford, United Kingdom
979	Padhraig Gormley	GlaxoSmithKline, Brentford, United Kingdom
980	Jimmy Liu	GlaxoSmithKline, Brentford, United Kingdom
981	Clarence Wang	Sanofi, Paris, France
982	Ethan Xu	Sanofi, Paris, France
983	Franck Auge	Sanofi, Paris, France
984	Clement Chatelain	Sanofi, Paris, France
985	Deepak Rajpal	Sanofi, Paris, France
986	Dongyu Liu	Sanofi, Paris, France
987	Katherine Call	Sanofi, Paris, France
988	Tai-He Xia	Sanofi, Paris, France
989	Beryl Cummings	Maze Therapeutics, San Francisco, CA, United States
990	Matt Brauer	Maze Therapeutics, San Francisco, CA, United States
991	Huilei Xu	Novartis, Basel, Switzerland
992	Amy Cole	Novartis, Basel, Switzerland
993	Jonathan Chung	Novartis, Basel, Switzerland

994	Jaison Jacob	Novartis, Basel, Switzerland
995	Katrina de Lange	Novartis, Basel, Switzerland
996	Jonas Zierer	Novartis, Basel, Switzerland
997	Mitja Kurki	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
998	Institute, Cambridge, MA	A, United States
999	Samuli Ripatti	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1000	Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1001	Juha Karjalainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
1002	Institute, Cambridge, MA	A, United States
1003	Aki Havulinna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1004	Juha Mehtonen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1005	Priit Palta	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1006	Shabbeer Hassan	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1007	Pietro Della Briotta Paro	loInstitute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1008	Wei Zhou	Broad Institute, Cambridge, MA, United States
1009	Mutaamba Maasha	Broad Institute, Cambridge, MA, United States
1010	Shabbeer Hassan	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1011	Susanna Lemmelä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1012	Manuel Rivas	University of Stanford, Stanford, CA, United States
1013	Aarno Palotie	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1014	Arto Lehisto	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1015	Andrea Ganna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1016	Vincent Llorens	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1017	Hannele Laivuori	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1018	Mari E Niemi	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1019	Taru Tukiainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1020	Mary Pat Reeve	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1021	Henrike Heyne	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1022	Nina Mars	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1023	Kimmo Palin	University of Helsinki, Helsinki, Finland

1024	Javier Garcia-Tabuenca	University of Tampere, Tampere, Finland
1025	Harri Siirtola	University of Tampere, Tampere, Finland
1026	Tuomo Kiiskinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1027	Jiwoo Lee	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
1028	Institute, Cambridge, MA	, United States
1029	Kristin Tsuo	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
1030	Institute, Cambridge, MA	, United States
1031	Amanda Elliott	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
1032	Institute, Cambridge, MA	, United States
1033	Kati Kristiansson	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1034	Mikko Arvas	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank,
1035	Helsinki, Finland	
1036	Kati Hyvärinen	Finnish Red Cross Blood Service, Helsinki, Finland
1037	Jarmo Ritari	Finnish Red Cross Blood Service, Helsinki, Finland
1038	Miika Koskinen	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,
1039	Helsinki	
1040	Olli Carpén	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,
1041	Helsinki	
1042	Johannes Kettunen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
1043	District, Oulu, Finland	
1044	Katri Pylkäs	University of Oulu, Oulu, Finland
1045	Marita Kalaoja	University of Oulu, Oulu, Finland
1046	Minna Karjalainen	University of Oulu, Oulu, Finland
1047	Tuomo Mantere	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
1048	District, Oulu, Finland	
1049	Eeva Kangasniemi	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,
1050	Tampere, Finland	
1051	Sami Heikkinen	University of Eastern Finland, Kuopio, Finland
1052	Arto Mannermaa	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,
1053	Kuopio, Finland	

1054	Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland
1055	Samuel Heron	University of Turku, Turku, Finland
1056	Dhanaprakash Jambulinga	m University of Turku, Turku, Finland
1057	Venkat Subramaniam Rat	inakannan University of Turku, Turku, Finland
1058	Nina Pitkänen	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku,
1059	Finland	
1060		
1061	Biobank directors	
1062	Lila Kallio	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku,
1063	Finland	
1064	Sirpa Soini	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1065	Jukka Partanen	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank,
1066	Helsinki, Finland	
1067	Eero Punkka	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,
1068	Helsinki	
1069	Raisa Serpi	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
1070	District, Oulu, Finland	
1071	Johanna Mäkelä	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,
1072	Tampere, Finland	
1073	Veli-Matti Kosma	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,
1074	Kuopio, Finland	
1075	Teijo Kuopio	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,
1076	Jyväskylä, Finland	
1077		
1078	FinnGen Teams	
1079	Administration	
1080	Anu Jalanko	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1081	Huei-Yi Shen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1082	Risto Kajanne	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1083	Mervi Aavikko	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

1	$\Lambda 0 I$
	1184
	VU

- 1086 Analysis

1087	Mitja Kurki	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
1088	Institute, Cambridge, MA	, United States
1089	Juha Karjalainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
1090	Institute, Cambridge, MA, United States	
1091	Pietro Della Briotta Parolo Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland	
1092	Arto Lehisto	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1093	Juha Mehtonen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1094	Wei Zhou	Broad Institute, Cambridge, MA, United States
1095	Masahiro Kanai	Broad Institute, Cambridge, MA, United States
1096	Mutaamba Maasha	Broad Institute, Cambridge, MA, United States
1097		

1098 Clinical Endpoint Development

1099	Hannele Laivuori	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1100	Aki Havulinna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1101	Susanna Lemmelä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1102	Tuomo Kiiskinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1103	L. Elisa Lahtela	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1104		
1105	Communication	

- 1106 Mari Kaunisto Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
- 1108 E-Science

1109	Elina Kilpeläinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1110	Timo P. Sipilä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1111	Georg Brein	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1112	Oluwaseun Alexander Da	a Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

1113	Awaisa Ghazal	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1114	Anastasia Shcherban	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1115		
1116	Genotyping	
1117	Kati Donner	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1118	Timo P. Sipilä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1119		
1120	Sample Collection Coo	ordination
1121	Anu Loukola	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,
1122	Helsinki	
1123		
1124	Sample Logistics	
1125	Päivi Laiho	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1126	Tuuli Sistonen	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1127	Essi Kaiharju	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1128	Markku Laukkanen	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1129	Elina Järvensivu	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1130	Sini Lähteenmäki	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1131	Lotta Männikkö	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1132	Regis Wong	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1133		
1134	Registry Data Operati	ons
1135	Hannele Mattsson	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1136	Kati Kristiansson	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1137	Susanna Lemmelä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1138	Sami Koskelainen	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1139	Tero Hiekkalinna	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1140	Teemu Paajanen	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1141		
1142		

1143 Sequencing Informatics

1144	Priit Palta	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland	
1145	Kalle Pärn Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland		
1146	Shuang Luo	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland	
1147	Vishal Sinha	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland	
1148			
1149	Trajectory		
1150	Tarja Laitinen	Pirkanmaa Hospital District, Tampere, Finland	
1151	Mary Pat Reeve Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland		
1152	Harri Siirtola University of Tampere, Tampere, Finland		
1153	Javier Gracia-Tabuenca	University of Tampere, Tampere, Finland	
1154	Mika Helminen	University of Tampere, Tampere, Finland	
1155	Tiina Luukkaala	University of Tampere, Tampere, Finland	
1156	Iida Vähätalo	University of Tampere, Tampere, Finland	
1157			
1158	Data protection officer		
1159	Tero Jyrhämä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland	
1160			
1161	FinBB - Finnish biobank	x cooperative	
1162	Marco Hautalahti		
1163	Laura Mustaniemi		
1164	Mirkka Koivusalo		
1165	Sarah Smith		
1166	Tom Southerington		
1167			
1168	Declaration of In	nterests	
1169	The authors declare n	o competing interests.	

1171 Ethics statement

1172	Patients and control subjects in FinnGe	n provided informed consent for bi	obank research, based on
1173	the Finnish Biobank Act. Alternatively,	separate research cohorts, collected	prior the Finnish Biobank
1174	Act came into effect (in September 201	3) and start of FinnGen (August 20	17), were collected based
1175	on study-specific consents and later tran	nsferred to the Finnish biobanks aft	er approval by Fimea, the
1176	National Supervisory Authority for Wel	lfare and Health. Recruitment proto	cols followed the biobank
1177	protocols approved by Fimea. The Coord	dinating Ethics Committee of the Ho	ospital District of Helsinki
1178	and Uusimaa (HUS) approved the Finn	Gen study protocol Nr HUS/990/20	17.
1179			
1180	The FinnGen study is approved by F	Finnish Institute for Health and W	Velfare (permit numbers:
1181	THL/2031/6.02.00/2017, T	THL/1101/5.05.00/2017,	THL/341/6.02.00/2018,
1182	THL/2222/6.02.00/2018, T	THL/283/6.02.00/2019,	THL/1721/5.05.00/2019,
1183	THL/1524/5.05.00/2020, and THL/236	54/14.02/2020), Digital and popula	tion data service agency
1184	(permit numbers: VRK43431/2017-3, V	VRK/6909/2018-3, VRK/4415/2019	9-3), the Social Insurance
1185	Institution (permit numbers: KELA 58/	522/2017, KELA 131/522/2018, KI	ELA 70/522/2019, KELA
1186	98/522/2019, KELA 138/522/2019, KE	ELA 2/522/2020, KELA 16/522/20	20 and Statistics Finland
1187	(permit numbers: TK-53-1041-17 and T	FK-53-90-20).	

1188

The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 6 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154, Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018, Finnish Clinical Biobank Tampere MH0004, Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001.

1195

The FINRISK data used for the study were obtained from THL Biobank with application number
BB2015_55.1 and UKBB data using the UK Biobank Resource with application number 22627.
The study was approved by the Estonian Committee on Bioethics and Human Research (approval
number 1.1-12/624).

1200 Figures and tables

1201 Figure 1: GWAS results for coronary atherosclerosis in FinnGen. Total number of independent 1202 genome-wide significant associations (GWS; $p < 5 \times 10^{-8}$) is 38, the lead variant in each marked with 1203 diamonds. Four novel associations for CVD- related phenotypes are highlighted with ± 750 Mb 1204 around the lead variant in the region as red and the lead variant marked with red diamond......10 1205 Figure 2: Phenome-wide association study (PheWAS) results for rs534125149. Total number of 1206 tested endpoints is 2 861 (A complete list of endpoints analyzed and their definitions is available at 1207 https://www.finngen.fi/en/researchers/clinical-endpoints). The dashed line represents the phenome-1208 wide significance threshold, multiple testing corrected by the number of endpoints = 0.05/2.861 =1209 1210 Figure 3: Comparison of the effects (OR) of rs534125149 and rs201988637 for 14 endpoints with 1211 p-value < 1.75×10-5 (PWS) for rs534125149.95% confidence intervals represented as grey lines.14 1212 Figure 4: Cumulative incidence plots for myocardial infarction. Red line represents carriers (homo-1213 or heterozygous) for either rs534125149 or rs201988637, and blue line represent non-carriers. 1214 1215 Figure 5: Results for pulse pressure association across all cohorts with splice acceptor variant 1216 1217 1218 1219
Table 2: Lead variants in novel loci associated with coronary atherosclerosis.